Korea Drug Development Fund (KDDF) & WCCT Global Announces Mutual Cooperation

WCCT Global announced today a mutual cooperation and business agreement with Korea Drug Development Fund (KDDF) located in Seoul, South Korea

WCCT Global announced today a mutual cooperation and business agreement with Korea Drug Development Fund (KDDF) located in Seoul, South Korea.

This will be only the second global network of this kind between a US Contract Research Organization (CRO) and KDDF. Through this alliance, KDDF hopes to seek help and to continue building ties for research institutions worldwide, in a cooperative effort for the development of new drugs, through educational forums, and training programs, etc. between Korea and the US.

When interviewed, WCCT's Chief Executive Officer, Dr. Kenneth T. Kim stated, "This is an exciting opportunity for WCCT Global to help Korean companies bring new medicinal products to the US and allow them to be represented and supported through the drug development process in the US."

In addition, Kim said, "We have been actively providing regulatory, drug development, and phase 1/2a services for Asian clients for nearly a decade, and we are extremely energized about the opportunity to work closely with Korean pharmaceutical companies wanting to develop new chemical entities (NCEs) globally starting in the US. With our access to Asian subjects, many Asian based clients can obtain their first in human data and Asian ethnic data in the same study, saving time and streamlining their global development plans. We see this as another great bridge to playing a partnering role and becoming the country caretaker for work brought to the US, as well as serving as a conduit for out-licensed compounds to Korean pharmaceutical companies. As a Korean American, I have had a longstanding personal interest in deepening these professional ties with Korean pharmaceutical companies."

KDDF's Chief Executive Officer, Dr. Dongho Lee stated, "It is meaningful that KDDF's effort to expand the global network is producing noticeable results. We hope that this agreement with WCCT will be another channel to provide important resources to the Korean investigators. We look forward to collaborating with WCCT to advance the drug development activities in Korea"

KDDF is a new drug development project established in 2011 with a collaborative effort of three healthcare-related Korean ministries. KDDF aims to advance drug development platforms and strategies and provides tailored consulting services to meet the needs of Korean investigators. One of the key activities of KDDF is establishing various channels to connect the global biopharmaceutical leaders and Korean investigators. Currently, there are 16 awarded projects in the portfolio, which span the whole drug development continuum and various therapeutic areas.

WCCT Global is a privately owned Full Service Contract Research Organization that owns and operates its own clinical pharmacology units (CPUs) that focus on early phase clinical development, Headquartered in Southern California with locations throughout the US. WCCT was founded in 1998 by Dr. Kenneth Kim, a board certified physician specializing in Internal Medicine, Allergy and Immunology. WCCT's CPU locations and access to an ethnically diverse population allows for a wide variety of study designs and therapeutic areas including Asian bridging/ethnic bridging. With over a 150 beds in two locations and over 60,000 square feet, a well-trained and experienced staff, advanced technological procedures coupled with a Full CRO operations team and services, WCCT brings the highest quality to the pharmaceutical and biotechnology industries.

In the field of pharmaceuticals, biotechnology, and medical devices- WCCT Global is an innovative leader for outsourced early phase drug development services both nationally and globally.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Signant Health is ramping up its virtual trial model after buying VirTrial to “truly digitize the operations of clinical study sites.”

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.